|Bid||3.9100 x 800|
|Ask||3.9200 x 800|
|Day's range||3.6100 - 3.9500|
|52-week range||1.7400 - 7.7500|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||N/A|
|Earnings date||08 May 2023 - 12 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.25|
SEATTLE, March 13, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022, wh
SEATTLE, March 10, 2023--Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.
SEATTLE, March 07, 2023--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.